Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc- μTP-L309C, a recombinant IgG1 Fc hexamer

High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases; however, there are challenges associated with product pro...

Source: BMC Immunology - December 4, 2019 Category: Allergy & Immunology Authors: Bonnie J. B. Lewis, Jade Ville, Megan Blacquiere, Selena Cen, Rolf Spirig, Adrian W. Zuercher, Fabian K äsermann and Donald R. Branch Tags: Research article Source Type: research